GeneDx (NASDAQ:WGS) Director Keith Meister Purchases 29,495 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) Director Keith Meister bought 29,495 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The stock was bought at an average price of $70.89 per share, for a total transaction of $2,090,900.55. Following the transaction, the director owned 3,088,124 shares of the company’s stock, valued at approximately $218,917,110.36. This trade represents a 0.96% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

GeneDx Price Performance

Shares of WGS traded up $3.48 during mid-day trading on Friday, hitting $85.48. 105,766 shares of the company were exchanged, compared to its average volume of 764,104. The stock has a market cap of $2.50 billion, a price-to-earnings ratio of -113.97 and a beta of 2.03. GeneDx Holdings Corp. has a 1-year low of $55.17 and a 1-year high of $170.87. The company has a 50 day moving average of $101.71 and a 200-day moving average of $122.42. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.34 and a current ratio of 2.46.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Monday, February 23rd. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.11 by $0.03. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%.The company had revenue of $120.99 million during the quarter, compared to analyst estimates of $120.80 million. Analysts expect that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Institutional Investors Weigh In On GeneDx

Several hedge funds and other institutional investors have recently bought and sold shares of WGS. Jones Financial Companies Lllp raised its stake in GeneDx by 664.3% during the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after purchasing an additional 186 shares during the period. Kestra Advisory Services LLC purchased a new stake in shares of GeneDx in the 4th quarter valued at approximately $27,000. Quarry LP increased its holdings in shares of GeneDx by 248.8% during the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after buying an additional 209 shares during the last quarter. Ramirez Asset Management Inc. acquired a new stake in shares of GeneDx during the 4th quarter worth approximately $33,000. Finally, Greenline Wealth Management LLC purchased a new stake in shares of GeneDx during the 4th quarter valued at approximately $33,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

WGS has been the topic of a number of research reports. Jefferies Financial Group set a $150.00 price objective on GeneDx in a report on Monday, February 23rd. Weiss Ratings reissued a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, January 21st. Wall Street Zen lowered shares of GeneDx from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. BTIG Research cut their price objective on shares of GeneDx from $200.00 to $170.00 and set a “buy” rating for the company in a report on Tuesday, February 24th. Finally, Wells Fargo & Company raised shares of GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 target price on the stock in a research note on Monday, February 9th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $150.71.

GeneDx News Roundup

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Large affiliated purchase: Corvex Management reported a purchase of GeneDx shares worth roughly $13.4 million, signaling institutional/insider confidence that can support the stock. Corvex management buys GeneDx (WGS) shares worth $13.4 million
• Positive Sentiment: Director purchases: Director Keith A. Meister made two recent buys — 140,026 shares on Mar 5 at ~$81.19 (~$11.37M) and 29,495 shares on Mar 3 at ~$70.89 (~$2.09M) — increasing his stake to over 3.2M shares. Large insider buys by a director typically signal confidence and can spur investor demand. SEC ownership filing — Keith A. Meister purchases
• Neutral Sentiment: Short-interest data shows 0 reported short interest as of Mar 5 (days-to-cover 0.0), which appears to be a data anomaly or non-material reading; it provides little actionable signal for directional pressure.
• Negative Sentiment: CEO sale: CEO Katherine Stueland sold 25,459 shares on Mar 4 at an average ~$78.61 (~$2.00M), reducing her direct ownership by ~39.7%. Significant insider sales can prompt investor concern about insiders taking liquidity. SEC Form 4 — CEO sale
• Negative Sentiment: CFO sale: CFO Kevin Feeley sold 6,187 shares on Mar 4 at the same avg price (~$78.61) for ~ $486k, trimming his stake by ~24.9%. Smaller than the institutional buys but adds to mixed insider signals. SEC Form 4 — CFO sale

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.